Objective Cyclosporine has been used for patients with nephrotic syndrome. Because of substantial interand intra-patient variability and a narrow therapeutic window, drug monitoring of cyclosporine is mandatory. To confirm the therapeutic effects of a cyclosporine microemulsion (CSAME), the absorption profile of the agent after preprandial administration was determined in steroid-resistant patients with refractory nephrotic syndrome. Methods Fourteen patients were enrolled into the study (mean age, 31.2±12; 6 men, 8 
Introduction

Cyclosporine, a calcineurin inhibitor immuno-suppressive agent, has beneficial effects in the treatment of steroidresistant and frequently relapsing nephrotic syndrome (1-4). The potency and duration of calcineurin inhibition by cyclosporine depend on the blood cyclosporine concentration and the period of time that effective inhibition is maintained
.
The high inter-individual variability in blood concentrations and narrow therapeutic index require dose adjustment according to trough concentrations (C0), 2 hours post-dose concentrations (C2) or the estimation of the area under the concentration curve (AUC) to avoid underdosage with treatment failure and overdosage with toxic effects after reanl transplantation (7-10). To prevent cyclosporine-induced nephropathy, however, maintaining the appropriate blood cyclosporine concentration within a narrow therapeutic window appears to be essential.
Recently, cyclosporine microemulsion (CSAME; Novartis Pharma, Basel, Switzerland) was introduced. When CSAME was administered postprandially, cyclosporine peak concentration appeared within 1-2 hours after administration, which is defined as high absorption. In some patients, however, cyclosporine absorption is delayed and the peak concentration does not occur within the first 2 hours after dosing. This delayed peak effect is defined as low cyclosporine absorption.
T a b l e 1 . P r e p r a n d i a l Ab s o r p t i o n P r o f i l e o f Cy c l o s p o r i n e Mi c r o e mu l s i o n
Preprandial administration of CSAME provided a more stable absorption profile in adult patients with refractory nephrotic syndrome (11) . However, the dose adjustment of CSAME and the clinical efficacy of this treatment have not been completely investigated. The aim of our study was to examine the effects of preprandial administration of CSAME on the clinical parameters in patients with refractory steroidresistant nephrotic syndrome. 
Subjects and Methods
From
F i g u r e 1 . Ab s o r p t i o n p r o f i l e i n a p a t i e n t wi t h s t e r o i d -r e s i st a n t n e p h r i t i c s y n d r o me f o l l o wi n g c y c l o s p o r i n e mi c r o e mu ls i o n ( 7 5 mg ) a d mi n i s t r a t i o n o n c e d a i l y b e f o r e a n d a f t e r b r e a k f a s t .
T a b l e 2 . Ch a n g e s i n Cl i n i c a l P a r a me t e r s b e f o r e a n d a f t e r 6 Mo n t h s o f Cy c l o s p o r i n e Mi c r o e mu l s i o n i n S t e r o i d -r e s i s t a n t P a t i e n t s wi t h Ref r a c t o r y Ne p h r o t i c S y n d r o me times in 3 patients as shown in
F i g u r e 2 . Co r r e l a t i o n b e t we e n AUC0 -4 a n d C0 ( A) , C1 ( B ) a n d C2 ( C)
mL. The mean C0 level was 41.17±19.9 ng/mL. In 83% of the patients, the cyclosporine peak concentration appeared within 1 hour after administration (C1). Figure 2 shows the correlation between AUC0-4 and C0, C1 and C2. A strong positive correlation was noted between AUC0-4 and C1 (R 2 = 0.90312) and C2 (R 2 =0.78431).
The mean steroid (prednisolone) dose was 40 mg/day when CSAME treatment was started, but a lowering of the dose to 17.5 mg/day (p<0.001) was achieved at 6 months after CSAME therapy. Figure 3 shows the absorption profile measured within 1 week from the start of CSAME treatment. The mean peak cyclosporine levels (Cmax) 
Discussion
The present study was designed to investigate whether preprandial administration of CSAME would result in disease remission in steroid-resistant patients with refractory nephrotic syndrome. First, we identified that complete remission was achieved 30% of the patients and the remaining patients were judged to achieve partial remission. Second, the single sampling point that best correlated with AUC0-4 was C1 or C2, and there was no correlation between AUC0-4 and C0. Third, mean C0 levels were low in all patients, indicating the inability of C0 to predict cyclosporine absorption status. Finally, CSAME administration reduced steroid dosages prescribed in these patients.
There have been a few studies that suggest optimal administration method of CSAME in the treatment of nephrotic syndrome based on pharmacokinetic parameters. The pharmacokinetic profile provides an indicator of the appropriate cyclosporine administration to obtain a sufficient ef- Ab s o r p t i o n p r o f i l e wh e n c y c l o s p o r i n e mi c r o e mu l s i o n wa s a d mi n i s t e r e d o n c e d a i l y b e  f o r e b r e a k f a s (15, 16) . AUC0-4 correlated well with C2 but not with C0; therefore, C2 monitoring has been proposed to be a more sensitive tool for monitoring cyclosporine absorption (17, 18) . Kusaba et al (11) reported the absorption profile of CSAME in adult patients with nephrotic syndrome. Preprandial administration provided a more stable absorption profile of cyclosporine compared with postprandial administration. From the correlation with AUC0-4, they concluded that C2, and not C0, is a reliable marker for monitoring cyclosporine exposure. When CSAME is administered preprandially, the bile acids and the drug would be effectively mixed before food enters the upper gastrointestinal tract, which may result in improved cyclosporine absorption (19) . Takeda et al (20) (11, 20) , we would support their data, suggesting that preprandial administration of CSAME is useful to achieve an absorption profile in steroid-resistant nephrotic syndrome. Second, we measured the absorption profile of CSAME in the same patients several times. This clinical approach seems to be not adequate for the determination of absorption profile of CSAME. However, the absorption profile is not stable even if the same dose of CSAME is administered to the same patient in a different study period. Thus, we propose that the absorption profile should be measured at least twice during the study period.
In conclusion, the current study showed the efficacy of preprandial administration of CSAME in steroid-resistant patients with refractory nephrotic syndrome. C1 
